JP2024539081A5 - - Google Patents

Info

Publication number
JP2024539081A5
JP2024539081A5 JP2024523275A JP2024523275A JP2024539081A5 JP 2024539081 A5 JP2024539081 A5 JP 2024539081A5 JP 2024523275 A JP2024523275 A JP 2024523275A JP 2024523275 A JP2024523275 A JP 2024523275A JP 2024539081 A5 JP2024539081 A5 JP 2024539081A5
Authority
JP
Japan
Prior art keywords
agent according
nucleic acid
acid sequence
sequence encoding
zinc finger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539081A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047079 external-priority patent/WO2023069478A1/en
Publication of JP2024539081A publication Critical patent/JP2024539081A/ja
Publication of JP2024539081A5 publication Critical patent/JP2024539081A5/ja
Pending legal-status Critical Current

Links

JP2024523275A 2021-10-20 2022-10-19 転写因子の抑圧によってcnsグリア集団を若返らせるための方法及び組成物 Pending JP2024539081A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163257827P 2021-10-20 2021-10-20
US63/257,827 2021-10-20
US202263350039P 2022-06-08 2022-06-08
US202263350041P 2022-06-08 2022-06-08
US202263350042P 2022-06-08 2022-06-08
US63/350,042 2022-06-08
US63/350,041 2022-06-08
US63/350,039 2022-06-08
PCT/US2022/047079 WO2023069478A1 (en) 2021-10-20 2022-10-19 Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors

Publications (2)

Publication Number Publication Date
JP2024539081A JP2024539081A (ja) 2024-10-28
JP2024539081A5 true JP2024539081A5 (cg-RX-API-DMAC7.html) 2025-10-14

Family

ID=84359179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024523274A Pending JP2024539080A (ja) 2021-10-20 2022-10-19 グリア前駆細胞を若返らせることによってミエリン欠乏症を処置するための組成物及び方法
JP2024523275A Pending JP2024539081A (ja) 2021-10-20 2022-10-19 転写因子の抑圧によってcnsグリア集団を若返らせるための方法及び組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024523274A Pending JP2024539080A (ja) 2021-10-20 2022-10-19 グリア前駆細胞を若返らせることによってミエリン欠乏症を処置するための組成物及び方法

Country Status (6)

Country Link
US (4) US20230190961A1 (cg-RX-API-DMAC7.html)
EP (2) EP4419679A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024539080A (cg-RX-API-DMAC7.html)
AU (2) AU2022369984A1 (cg-RX-API-DMAC7.html)
CA (3) CA3234634A1 (cg-RX-API-DMAC7.html)
WO (3) WO2023069484A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230190961A1 (en) 2021-10-20 2023-06-22 University Of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
IL319917A (en) * 2022-10-19 2025-05-01 Univ Rochester Methods and compositions for renewing glial populations of the central nervous system with expression of the transcription factor BCL11A

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US275794A (en) 1883-04-10 Eugene ward
US748529A (en) 1903-09-03 1903-12-29 Troy Laundry Machinery Co Ltd Marking-machine.
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
DE69942334D1 (de) 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
US20030223972A1 (en) 2002-02-15 2003-12-04 Goldman Steven A. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
US20040029269A1 (en) 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2580515C (en) 2004-10-04 2017-05-02 National Research Council Of Canada Expression system, components thereof and methods of use
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US20150362508A1 (en) 2013-01-30 2015-12-17 Benaroya Research Institute At Virginia Mason Effector t cell rsistance
US12522594B2 (en) 2017-02-09 2026-01-13 Deutsches Krebsforschungszentrum 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US12303549B2 (en) 2018-06-21 2025-05-20 University Of Rochester Methods of treating or inhibiting onset of Huntington's disease
AU2019342741B2 (en) * 2018-09-19 2025-12-11 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
EP3923962A2 (en) * 2019-02-13 2021-12-22 University of Rochester Gene networks that mediate remyelination of the human brain
EP4099993A4 (en) 2020-02-06 2024-03-13 Emerald Health Pharmaceuticals Inc. COMPOSITION AND METHOD FOR TREATING AND PREVENTING CARDIAC, LUNG, SKIN AND KIDNEY FIBROSIS
IL311610A (en) 2021-09-21 2024-05-01 Scribe Therapeutics Inc Engineered CASX suppressor systems
US20230241118A1 (en) 2021-10-20 2023-08-03 University Of Rochester Rejuvenation treatment of age-related white matter loss
US20230190961A1 (en) 2021-10-20 2023-06-22 University Of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells

Similar Documents

Publication Publication Date Title
van Zundert et al. Silencing strategies for therapy of SOD1-mediated ALS
Wang et al. Lin28 signaling supports mammalian PNS and CNS axon regeneration
Iannitti et al. Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS
Hoye et al. Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis
Yamashita et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9‐ADAR 2 delivery to motor neurons
Hwang et al. The gene silencing transcription factor REST represses miR-132 expression in hippocampal neurons destined to die
Van Gestel et al. shRNA-induced saturation of the microRNA pathway in the rat brain
Kotowska-Zimmer et al. A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
US20240425856A1 (en) Compositions and Methods for Treating Cag Repeat Diseases
WO2023104028A1 (zh) 非编码rna介导的神经性疾病治疗
Hoshino et al. The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury
Zhang et al. Differential exosomal microRNA profile in the serum of a patient with depression
Wang et al. Efficient and precise processing of the optimized primary artificial MicroRNA in a Huntingtin-Lowering Adeno-Associated viral gene therapy in vitro and in mice and nonhuman primates
JP2024539080A5 (cg-RX-API-DMAC7.html)
Kuzma-Kozakiewicz et al. New therapeutic targets for amyotrophic lateral sclerosis
JP2025516186A5 (cg-RX-API-DMAC7.html)
CN119451703A (zh) 髓鞘病症的治疗
US20220098616A1 (en) ISL1 and LHX3 VECTOR
US20220081690A1 (en) Use of mir-204 inhibitor to increase nurr1 protein expression
Velinov Gene therapy for Fragile X Syndrome, challenges, and promises
US20260041793A1 (en) Viral vector
EP4689120A2 (en) Compositions and methods for treating cag repeat diseases
US20220106614A1 (en) Dlx2 vector
Yang et al. Optimization of miR-22 expression cassette for rAAV delivery on diabetes
US10426846B2 (en) OLIG1 mini-promoters: PIe305